Kornimate/medical-research-clean huggingface dataset:
heterogeneity of metastatic neuroendocrine tumors as determined with 18f-dihydroxyphenylalanine-pet /ct, a retrospective analysis

Conditions: Neuroendocrine Tumors

Summary: in an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. tumour load in net patients can be measured with fluorine-18-l-dihydroxyphenylalaninepositron emission tomography (18f-dopa-pet) scan. this aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal net by determining the differences in tracer uptake measured on a 18f- dopa-pet scan retrospectively.

in an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. tumour load in net patients can be measured with fluorine-18-l-dihydroxyphenylalanine positron emission tomography (18f-dopa-pet) scan. this aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal net by determining the differences in tracer uptake measured on a 18f- dopa-pet scan in retrospect.

Eligibility criteria:
inclusion criteria: * age ≥18 years * diagnosis of intestinal net diagnosed by a dedicated net specialist * more than one positive lesion on the 18f-dopa-pet scan. * available ct-scan within 6 months before or after the 18f-dopa-pet-scan. exclusion criteria: * no clinical data available at the umcg, besides the results of the dopa pet scan.
effectivity and efficiency of turning frequencies: a randomised controlled trial

Conditions: Pressure Ulcer Lesions (Grade 2 or More)

Summary: evaluation of the difference in pressure ulcer incidence or the time to develop pressure ulcers depending on the turning frequencies.

evaluation of the difference in pressure ulcer incidence or the time to develop pressure ulcers depending on the turning frequencies.

Eligibility criteria:
inclusion criteria: * non-blanchable erythema above a bony prominence * informed consent exclusion criteria: * pressure ulcers grade 3 or 4 * turning contra-indicated based on medical grounds
a randomized controlled trial of the uresta continence pessary

Conditions: Stress Urinary Incontinence

Summary: stress urinary incontinence (sui) is defined as the involuntary loss of urine with an increase in abdominal pressure, caused either by a loss of support under the bladder neck, or intrinsic urethral sphincter deficiency. it is a common problem in women that can significantly impact quality of life, with up to 30% developing sui at some point in their lifetime. the most commonly utilized treatments for sui include either pelvic floor (kegel) exercises, or surgery. many women find kegel exercises unsatisfactory, but are reluctant to undergo a surgical procedure. also, women who are poor candidates for surgery have limited options if kegel exercises are unsuccessful. over the years, there have been numerous attempts to develop effective non-surgical alternatives for treating sui, but the results have been variable and the available data on efficacy limited. a new intravaginal incontinence pessary (uresta) has been developed for treating stress incontinence, and is currently available in canada via a medical distributor. the self-positioning device is initially fitted by a healthcare provider, but then can subsequently placed by the patient as needed. uresta is designed to be easily inserted into the vagina and spontaneously fall into position, providing support beneath the urethra. a single, uncontrolled study of 21 women showed that uresta significantly reduces urinary incontinence measures, with no reported complications. using questionnaires, a 47% reduction in self-reported sui symptoms was demonstrated. pad weight following a pad test, an objective assessment of urine loss, showed a 50% reduction in leakage. this trial is intended to be a short-term assessment of the efficacy of the uresta device, using a placebo arm in order to remove any of the possible sources of patient biases. the placebo ("sham") group will be obtained by placing a flexible silastic ring (inactivated estring) high in the vagina where it will not alter urethral forces. the aim is to unequivocally determine whether the uresta device provides the necessary urethral support to stop urine leakage from stress incontinence. the hypothesis is that the uresta device will significantly reduce urinary losses from baseline, shown as a significant reduction pad weight following a pad test with the device in place.


Eligibility criteria:
inclusion criteria: * urodynamic diagnosis of stress urinary incontinence exclusion criteria: * urodynamic diagnosis of mixed incontinence * bladder capacity less than 300mls * post-void residual over 100mls * pelvic organ prolapse greater than pop-q stage 2 * hematuria * undiagnosed vaginal bleeding * current pregnancy * previous incontinence or prolapse surgery * failed use of an incontinence pessary * physically unable to perform the activities included in the pad test

Keywords: urinary incontinence, stress pessary conservative management
myosteatosis in oeso-gastric cancer: clinical impacts

Conditions: Esophageal Cancer; Gastric Cancer; Myopenia; Adipose Tissue Tumor

Summary: the aim of this project is to study the presence of cancer-associated adipocytes in oesogastric cancers and their possible links with myosteatosis. this research project has a retrospective component, the aim of which is to analyse the body component based on imaging in patients with oesogastric neoplasia in order to determine the incidence of myosteatosis and to study the relationship with oncological and prognostic data. the second part of the project is prospective and will collect biological material (skeletal muscle, adipose tissue, tumour, blood) for histological, molecular and genomic analyses and will analyse muscle function in patients with oesogastric cancer. it will address the role of adipocytes in the tumour microenvironment of oesogastric cancer, focusing on their interactions with the observed muscle myosteatosis and prognosis. in the future, it will help to identify signalling pathways, targets and patients who could benefit from appropriate treatment.

oesophageal and gastric cancer pose a significant challenge to caregivers, both in terms of the complexity of its presentation and its treatment. at diagnosis, patients often present with malnutrition associated with sarcopenia, which has a significant impact on morbidity and mortality. although loss of muscle mass has received much attention in cancer, muscle quality, particularly the accumulation of fat in muscle named "myosteatosis", may be considered as a better predictor of a patient's physical condition and ability to recover from cancer treatments. studying the tumor microenvironment is essential to understanding the mechanisms underlying disease progression. cancer-associated adipocytes (caa), a major component of this tumor microenvironment, provide an interface for dialogue with the tumor through the secretion of pro-inflammatory cytokines, metalloproteases and the release of free fatty acids. they have been described as capable of stimulating tumor progression, particularly in breast cancer. however, their presence in oesogastric cancer and possible links with myosteatosis have not been described.

Eligibility criteria:
inclusion criteria: * patients with cancer of the oesophagus, oeso-gastric junction or stomach * treatment and estimated survival of more than 3 months * signed informed consent * \> 18 years of age exclusion criteria: * neuromuscular or orthopedic pathology * cognitive disorders * psychiatric disorders * inability to communicate in french or english
cardiomyopathy arrhythmia risk evaluation

Conditions: Cardiomyopathy

Summary: this study will evaluate the prognostic utility of novel ecg markers of electrical instability in patients with cardiomyopathy.

baseline ecg markers of electrical instability will be measured in patients with cardiomyopathy. these ecg markers will be evaluated from a clinical holter recording. all patients will have a primary implantable cardioverter defibrillator (icd) as part of their clinical care. patients will be followed prospectively for 2 years to evaluate the primary outcome of appropriate icd shocks. multivariable modelling will be performed to determine whether the ecg markers of electrical instability independently predict the primary clinical outcome.

Eligibility criteria:
inclusion criteria: * cardiomyopathy, primary prevention icd exclusion criteria: * brady-pacing requirement
well-formulated ketogenic diet polycystic kidney disease

Conditions: Polycystic Kidney Disease

Summary: this is a prospective study to determine ketogenic diet effect on httkv, gfr, microalbuminuria. this is a single-center study of 20 patients with adpkd and deemed high risk for progression to esrd. this determined by combination of features of adpkd and httkv as assessed by prior computed tomography (ct) or mri. patients will be recruited from the polycystic kidney disease (pkd) clinic at ohio state university wexner medical center. enrolled patients will have mri for httkv, urinary studies, blood tests at baseline, 6 months, and 52 weeks. blood for gfr will be assessed three times over the course of the study including baseline, 6 months, and 1 year. participants will follow ketogenic diet for 52 weeks. investigatory diet team will manage the ketogenic diet.


Eligibility criteria:
inclusion criteria: * age 18-65 years old * diagnosis of adpkd by imaging and/or genetic testing * gfr ≥ 25 mg/dl * patients at risk for rapid progression of adpkd: mayo class 1c-1e along with any other high risk features including early decline in gfr, hypertension onset ≤ 35 years of age, urologic events ≤ 35 years of age, pkd 1 truncating mutation and propkd score of 4 or higher as determined by the treating physician * no changes of medications within the last three months. * able to comply with dietary intervention * ability to sign informed consent exclusion criteria: * patients currently being treated with tolvaptan * diagnosed with diabetes. * pregnancy * contraindications to mri * ketogenic diet within the last three months * severe kidney disease with gfr \< 25 mg/dl * unable to purchase food for the diet intervention * gastrointestinal disorders that will interfere with diet intervention * chronic alcohol or drug abuse
fecal amino acids，gut taste receptors and irritable bowel syndromes

Conditions: Irritable Bowel Syndrome

Summary: clinical data, fresh feces and intestinal mucosal tissues of patients with diarrheal ibs were collected. high performance liquid chromatography, immunohistochemistry and immunofluorescence were used to study the amino acid levels in feces of patients with ibs, the expression of taste receptors in intestinal mucosa, and the correlation between symptoms of abdominal pain and diarrhea and the expression of taste receptors, so as to obtain the conclusion that "intestinal amino acid perception abnormalities exist in patients with ibs. and correlated with clinical symptoms."


Eligibility criteria:
inclusion criteria: * patients with ibs who meet the rome iv diagnostic criteria: 1. that is, recurrent abdominal pain, with symptoms occurring at least 1 day per week or at least 3 days per month on average in the last 3 months, combining 2 or more of the following: 1. related to defecation; 2. accompanied by changes in the frequency of bowel movements; 3. accompanied by changes in fecal characteristics (appearance). (symptoms appeared at least 6 months before diagnosis, and above diagnostic criteria were met in the last 3 months) 2. age ≥18 years old. exclusion criteria: * 1. history of celiac disease and other organic intestinal diseases, metabolic diseases (thyroid dysfunction, diabetes, etc.); (2) serious neurological, mental and psychological diseases, or accompanied by serious organ dysfunction; 3. abdominal surgery; 4. pregnant, possible pregnant and lactating patients; 5. history of colonoscopy in the past 1 year; 6. declined to participate in the study.
effect of alfacalcidol to respiratory infection and immune response of indonesian elderly

Conditions: Frail Elderly Syndrome; Elderly Infection

Summary: vitamin d has been known to influence immune response through vitamin d receptor in immune cells, but only few has been known about the effect alfacalcidol, a vitamin d analog to immune system. in elderly, immune disregulation or immunosenecence have great impact to infection response. this study is aimed to determine the effect of alfacalcidol supplementation in vitro and in vivo to respiratory infection incidence and inflammatory markers, as well as t cell lymphocyte subset in indonesian elderly patients.

this study consist of 2 designs. first is in vitro study to investigate the effect of alfacalcidol supplementation to il-6, il-10 and ifn gamma regulation in peripheral blood mononuclear cells (pbmc) of elderly and second design is randomised controlled trial to evaluate the effect of 3 months supplementation of alfacalcidol 0,5 mcg in respiratory infection, antibiotic use, inflammatory markers, cd4/cd8 ratio and cd8+ cd28+ in indonesian elderly with various level of frailty syndrome.

Eligibility criteria:
inclusion criteria: * elderly age more than 60 * willing to join research exclusion criteria: * in acute infection * using nsaid or steroid * liver failure * hypercalcemia

Keywords: immunosenescence
influence of a lifestyle intervention in preschool children on physiological and psychological parameters

Conditions: Obesity

Summary: childhood obesity and low fitness tracks into adulthood and carries significant co-morbidities. the investigators test the hypothesis that a multidisciplinary multilevel lifestyle intervention in preschool children in the french and german speaking part of switzerland during one school-year results in a smaller increase in body mass index (bmi) and a larger increase in aerobic fitness.

we will assess the effect of this multidisciplinary intervention in a multicenter cluster randomized controlled trial including a total of 40 kindergarten classes in the french (canton vaud) and in the german (canton st. gallen) speaking part of switzerland. health promoters, trained in physical education, will receive further postgraduate training (in nutrition, education, psychology) and will then in reward teach several kindergarten teachers hands-on. these trained health promoters will intervene on the level of the kindergarten teacher, the parents, the local community and also on the level of the children following a professional pre-specified curriculum in the kindergarten that focuses primarily on physical activity, healthy nutrition, media use and sleep duration. the curriculum also includes information evenings, workshops and fun weekly homework packages. special attention will be paid to establish a curriculum that reaches also socio-cultural high risk groups living in switzerland. measurements will be performed before and after the intervention.

Eligibility criteria:
inclusion criteria: * healthy kindergarten children exclusion criteria: * children with severe chronic disease (restricting physical activity)

Keywords: childhood children obesity physical activity nutrition fitness family
comparative effects of dual task training and embodied learning on dual task performance in children with down syndrome

Conditions: Down Syndrome

Summary: down syndrome is caused by an extra copy of chromosome 21, characterized by impaired motor skills, especially difficulties with coordination, and cognitive impairment. improving these abilities is essential to raising the affected children's quality of life and everyday functioning. dual task learning and embodied learning stand out among other interventions as effective strategies. while embodied learning uses physical motions to support cognitive growth, dual task learning mixes motor and cognitive tasks concurrently, testing the brain's capacity for multitasking. the purpose of this study is to compare how well embodied learning and dual task training work to improve dual task performance in kids with down syndrome. this study contains 22 participants age 7 to12 years and excludes participants with other neurological or orthopedic disorders, is focused on individuals who match the inclusion criteria children that are being able to follow instructions. the participants will be referred by allama iqbal school sialkot and children hospital sialkot. to test changes in motor coordination and balance, assessment tools such as the pediatric balance scale (pbs), timed up and go test, single leg stance test, four stage balance test, and 30-second sit to stand test will be used. in order to evaluate cognitive engagement and the development of motor skills, dual task training setups (such as walking while labelling objects or balancing while solving puzzles) as well as embodied learning activities (such as gesture-based learning, physical storytelling, yoga, and sensory play art) will be used. the purpose of this research is to offer useful knowledge about the effectiveness and practicality of various interventions in improving the everyday functioning and quality of life of children with down syndrome.


Eligibility criteria:
inclusion criteria: * children diagnosed with down syndrome * age 7 to 12 years * ability to follow instructions effectively exclusion criteria: * neurological conditions (cerebral palsy or epilepsy) * orthopedic conditions (foot abnormalities,s hip dysplasia) * significant sensory impairments (e.g., severe hearing or vision impairments.

Keywords: down syndrome, motor coordination, motor skills, psychomotor performance, cognitive dysfunction
web-based genetic research on lupus

Conditions: Systemic Lupus Erythematosus

Summary: the goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's dna and this disease, and second, to apply this understanding to drug development efforts with the investigator's partners at pfizer.

lupus is a difficult disease to diagnose and one that's difficult to manage, given the lack of specific medicines to treat lupus and the side-effects of current medications. the investigators believe genetics may play a critical role in developing better lupus diagnoses and treatments. if individuals are eligible to participate, the investigators will send a 23andme dna saliva kit at no cost. participants will be asked to take a 15 minute online survey with questions about their lupus experience, symptoms and response to treatments, in addition to five additional bi-monthly short surveys and one final study survey during the 12-month participation. learn more and join the lupus study today: https://www.23andme.com/lupus/

Eligibility criteria:
inclusion criteria: * diagnosed with lupus by a qualified physician. * consents to have 23andme (via a partner) contact the physician to obtain medical record information * willing to submit a saliva sample for dna testing and complete online surveys related to condition * at least 6 years old (minors under 18 require parental consent to enroll) * access to the internet * resides in the united states exclusion criteria: -

Keywords: lupus systemic lupus erythematosus (sle) genetic online genome wide association systemic lupus erythematosus genome wide association study (gwas)
rituximab plus bendamustine as front line treatment in frail elderly (>70 years) patients with dlbcl: a phase ii multicenter study of the fil

Conditions: Diffuse Large B-cell Lymphoma

Summary: the purpose of the study is to evaluate feasibility and efficacy of rituximab-bendamustine (r-b)combination in elderly patients affected by diffuse large b-cell lymphoma and defined as frail according to cga.


Eligibility criteria:
inclusion criteria: * histologically proven cd20 positive diffuse large b-cell non-hodgkin's lymphoma * age \> 70 years * no previous treatment * frail patients defined as follows (see appendices b-e) age \> 80 years with unfit profile, i.e. * adl \> 5 residual functions * iadl \> 6 residual functions * cirs 5-8 co-morbidities of grade 2 or age \< 80 years with * adl \< 4 residual functions, or * iadl \< 5 residual functions, or * cirs : 1 co-morbidity of grade 3-4, or \> 8 co-morbidities of grade 2 * life expectancy \> 6 months * written informed consent * accessibility of patient for treatment and follow up exclusion criteria: * history of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer * previous exposure to cytotoxic agents * suspect or clinical evidence of cns involvement by lymphoma * hbsag, hcv or hiv positivity; hbcab positivity is accepted only with concomitant treatment with lamivudine * ast /alt \> twice upper the normal range; bilirubin \> twice upper the normal range; serum creatinine \> 2.5 mg /dl * evidence of any severe active acute or chronic infection * concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy * senile dementia * any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
neoadjuvant tamoxifen in locally advanced breast cancer in a low/middle income country

Conditions: Breast Cancer; Breast Neoplasms

Summary: this study evaluates the feasibility and efficacy of neoadjuvant tamoxifen for patients with locally advanced hormone receptor positive breast cancer in a low/middle income country.

this is a single arm feasibility study of neoadjuvant tamoxifen for locally advanced hormone receptor positive breast cancer in a low-resource setting in a middle-income country (guatemala). patients will be treated with tamoxifen for four to six weeks, then have an on-treatment biopsy to assess ki-67. if ki-67 is less than or equal to 10%, the patient will continue on tamoxifen for a total of 4 months; if ki-67 is greater than 10% or there is clinical progression, patients will be taken off study. the study will evaluate the proportion of patients treated with four months of tamoxifen who undergo definitive surgery and the clinical and pathologic response rates.

Eligibility criteria:
inclusion criteria: * patient evaluated and treated at incan * patients must provide informed consent * patient must be ≥ 18 years of age. * life expectancy ≥ 6 months * clinical locally advance breast cancer (stage iib or iii) * pathologically confirmed diagnosis of estrogen receptor (er)-positive or progesterone receptor (pr)-positive breast cancer with er or pr allred score \> 4 * patient must have an ecog performance status of 0-2 * patients must be able to swallow and retain oral medication exclusion criteria: * patient must not have received any prior chemotherapy, radiation therapy, or biologic therapy for invasive breast cancer within the past five years * patient must not be pregnant or nursing * patient must not have had any prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease-free for five years. * women of childbearing age unable or unwilling to use contraception

Keywords: breast neoplasms breast cancer locally advanced breast cancer neoadjuvant endocrine therapy tamoxifen low and middle income country